Top Markets
#1 Doge Strategy Doge Strategy +1,105,414.43%
#2 Noon Noon +10,549.79%
#3 Siren Siren +110.82%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +43.50%
#6 Gigachad Gigachad +25.48%
#7 Ontology Ontology +20.07%
#8 TRIA TRIA +18.98%
#9 Echelon Prime Echelon Prime +18.98%
#10 Win Win +17.98%
Coin of the day
Doge Strategy Doge Strategy
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Peringkat dalam Saham #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Harga Saham
$0.0416118
Kapitalisasi Pasar
$12.78M
Perubahan (1 hari)
1.72%
Perubahan (1 tahun)
-22.01%
Negara
AU
Perdagangan Noxopharm Limited (NOX)

Kategori

Healthcare
Laba untuk Noxopharm Limited (NOX)
Laba pada Dec 2025 TTM: $-4.82M
Menurut laporan keuangan terbaru dari Noxopharm Limited, laba saat ini perusahaan adalah $-4.82M. Pada tahun 2024, perusahaan memperoleh laba sebesar $-3.99M, peningkatan dibandingkan laba tahun 2023 sebesar $-14.02M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Noxopharm Limited dari 2016 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $-4.82M 49.79%
2025 $-3.22M -19.45%
2024 $-3.99M -71.53%
2023 $-14.02M -15.43%
2022 $-16.58M 136.55%
2021 $-7.01M 23.32%
2020 $-5.68M -50.43%
2019 $-11.46M -19.51%
2018 $-14.24M 507.24%
2017 $-2.35M 334.19%
2016 $-540.21K 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -424,852.71%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -96,506.98%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -108,705.27%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -44,485.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -33,617.45%
AU